DOCSLIB.ORG

Multi-Tier Enhanced Drug List Updates July 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Multi-Tier Enhanced Drug List Updates July 2021 Multi-Tier Enhanced Drug List Updates July 2021 Brand/Generic TRADE NAME (generic name) or generic name Product Description of Change AFINITOR (everolimus tab 10 mg) Brand Addition ARANESP ALBUMIN FREE (darbepoetin alfa soln inj 100 mcg/ml) Brand Addition ARANESP ALBUMIN FREE (darbepoetin alfa soln inj 200 mcg/ml) Brand Addition ARANESP ALBUMIN FREE (darbepoetin alfa soln inj 25 mcg/ml) Brand Addition ARANESP ALBUMIN FREE (darbepoetin alfa soln inj 300 mcg/ml) Brand Addition ARANESP ALBUMIN FREE (darbepoetin alfa soln inj 40 mcg/ml) Brand Addition ARANESP ALBUMIN FREE (darbepoetin alfa soln inj 60 mcg/ml) Brand Addition ARANESP ALBUMIN FREE (darbepoetin alfa soln prefilled syringe 10 mcg/0.4ml) Brand Addition ARANESP ALBUMIN FREE (darbepoetin alfa soln prefilled syringe 150 mcg/0.3ml) Brand Addition ARANESP ALBUMIN FREE (darbepoetin alfa soln prefilled syringe 500 mcg/ml) Brand Addition ATRIPLA (efavirenz-emtricitabine-tenofovir df tab 600-200-300 mg) Brand Removal, generics available AZITHROMYCIN (azithromycin powd pack for susp 1 gm) Brand Addition CARBAGLU (carglumic acid tab 200 mg) Brand Addition COMBIVENT RESPIMAT (ipratropium-albuterol inhal aerosol soln 20-100 mcg/act) Brand Addition COTELLIC (cobimetinib fumarate tab 20 mg (base equivalent)) Brand Addition CRINONE (progesterone vaginal gel 4%) Brand Addition CRINONE (progesterone vaginal gel 8%) Brand Addition DILANTIN (phenytoin sodium extended cap 30 mg) Brand Addition EMCYT (estramustine phosphate sodium cap 140 mg) Brand Addition KESIMPTA (ofatumumab soln auto-injector 20 mg/0.4ml) Brand Addition LATUDA (lurasidone hcl tab 120 mg) Brand Addition LATUDA (lurasidone hcl tab 20 mg) Brand Addition LATUDA (lurasidone hcl tab 40 mg) Brand Addition LATUDA (lurasidone hcl tab 60 mg) Brand Addition LATUDA (lurasidone hcl tab 80 mg) Brand Addition LOTEMAX (loteprednol etabonate ophth oint 0.5%) Brand Addition LOTEMAX SM (loteprednol etabonate ophth gel 0.38%) Brand Addition LUMIGAN (bimatoprost ophth soln 0.01%) Brand Addition MAYZENT STARTER PACK (siponimod fumarate tab 0.25 mg (12) starter pack) Brand Addition MESNEX (mesna tab 400 mg) Brand Addition MULTAQ (dronedarone hcl tab 400 mg (base equivalent)) Brand Addition NEULASTA (pegfilgrastim soln prefilled syringe 6 mg/0.6ml) Brand Addition NEULASTA ONPRO KIT (pegfilgrastim soln prefilled syringe kit 6 mg/0.6ml) Brand Addition NEXIUM (esomeprazole magnesium for delayed release susp pack 2.5 mg) Brand Addition NEXIUM (esomeprazole magnesium for delayed release susp packet 5 mg) Brand Addition norethindrone ace-ethinyl estradiol-fe tab 1 mg-20 mcg (24) Generic Removal NYVEPRIA (pegfilgrastim-apgf soln prefilled syringe 6 mg/0.6ml) Brand Addition OZEMPIC (semaglutide soln pen-inj 1 mg/dose (4 mg/3ml)) Brand Addition PLEGRIDY (peginterferon beta-1a im soln prefilled syr 125 mcg/0.5ml) Brand Addition PREDNISOLONE SODIUM PHOSPHATE (prednisolone sodium phosphate ophth soln 1%) Brand Addition Continued July 2021 | Multi-Tier Enhanced Drug List Updates Brand/Generic TRADE NAME (generic name) or generic name Product Description of Change PREDNISONE (prednisone oral soln 5 mg/5ml) Brand Addition PRENATAL 19 (*prenatal vit w/ dss-fe fumarate-fa tab 29-1 mg***) Brand Addition PRENATAL 19 (*prenatal vit w/ fe fumarate-fa chew tab 29-1 mg***) Brand Addition PROPRANOLOL HCL (propranolol hcl oral soln 20 mg/5ml) Brand Addition PROPRANOLOL HCL (propranolol hcl oral soln 40 mg/5ml) Brand Addition PURIXAN (mercaptopurine susp 2000 mg/100ml (20 mg/ml)) Brand Addition REDITREX (methotrexate soln prefilled syringe 10 mg/0.4ml) Brand Addition REDITREX (methotrexate soln prefilled syringe 12.5 mg/0.5ml) Brand Addition REDITREX (methotrexate soln prefilled syringe 15 mg/0.6ml) Brand Addition REDITREX (methotrexate soln prefilled syringe 17.5 mg/0.7ml) Brand Addition REDITREX (methotrexate soln prefilled syringe 20 mg/0.8ml) Brand Addition REDITREX (methotrexate soln prefilled syringe 22.5 mg/0.9ml) Brand Addition REDITREX (methotrexate soln prefilled syringe 25 mg/ml) Brand Addition REDITREX (methotrexate soln prefilled syringe 7.5 mg/0.3ml) Brand Addition SE-NATAL 19 (*prenatal vit w/ dss-fe fumarate-fa tab 29-1 mg***) Brand Addition SE-NATAL 19 (*prenatal vit w/ fe fumarate-fa chew tab 29-1 mg***) Brand Addition SIMBRINZA (brinzolamide-brimonidine tartrate ophth susp 1-0.2%) Brand Addition SYNJARDY (empagliflozin-metformin hcl tab 12.5-1000 mg) Brand Addition SYNJARDY (empagliflozin-metformin hcl tab 12.5-500 mg) Brand Addition SYNJARDY (empagliflozin-metformin hcl tab 5-1000 mg) Brand Addition SYNJARDY (empagliflozin-metformin hcl tab 5-500 mg) Brand Addition SYNJARDY XR (empagliflozin-metformin hcl tab er 24hr 10-1000 mg) Brand Addition SYNJARDY XR (empagliflozin-metformin hcl tab er 24hr 12.5-1000 mg) Brand Addition SYNJARDY XR (empagliflozin-metformin hcl tab er 24hr 25-1000 mg) Brand Addition SYNJARDY XR (empagliflozin-metformin hcl tab er 24hr 5-1000 mg) Brand Addition TABLOID (thioguanine tab 40 mg) Brand Addition TRUVADA (emtricitabine-tenofovir disoproxil fumarate tab 100-150 mg) Brand Removal, generics available TRUVADA (emtricitabine-tenofovir disoproxil fumarate tab 133-200 mg) Brand Removal, generics available TRUVADA (emtricitabine-tenofovir disoproxil fumarate tab 167-250 mg) Brand Removal, generics available TRUVADA (emtricitabine-tenofovir disoproxil fumarate tab 200-300 mg) Brand Removal, generics available VELPHORO (sucroferric oxyhydroxide chew tab 500 mg) Brand Addition VIMPAT (lacosamide oral solution 10 mg/ml) Brand Addition VIMPAT (lacosamide tab 100 mg) Brand Addition VIMPAT (lacosamide tab 150 mg) Brand Addition VIMPAT (lacosamide tab 200 mg) Brand Addition VIMPAT (lacosamide tab 50 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate cap 10 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate cap 20 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate cap 30 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate cap 40 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate cap 50 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate cap 60 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate cap 70 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate chew tab 10 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate chew tab 20 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate chew tab 30 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate chew tab 40 mg) Brand Addition VYVANSE (lisdexamfetamine dimesylate chew tab 50 mg) Brand Addition Continued July 2021 | Multi-Tier Enhanced Drug List Updates Brand/Generic TRADE NAME (generic name) or generic name Product Description of Change VYVANSE (lisdexamfetamine dimesylate chew tab 60 mg) Brand Addition XELJANZ (tofacitinib citrate oral soln 1 mg/ml (base equivalent)) Brand Addition XTANDI (enzalutamide tab 40 mg) Brand Addition XTANDI (enzalutamide tab 80 mg) Brand Addition ZOKINVY (lonafarnib cap 50 mg) Brand Addition ZOKINVY (lonafarnib cap 75 mg) Brand Addition ZYLET (loteprednol etabonate-tobramycin ophth susp 0.5-0.3%) Brand Addition Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC. July 2021 | Multi-Tier Enhanced Drug List Updates 4621-E HCSC © Prime Therapeutics LLC 07/21.
Load more

Recommended publications
  • Confidential: for Review Only
    BMJ Confidential: For Review Only The risk of fall and fracture with the initiation of a prostate - selective alpha antagonist Journal: BMJ Manuscript ID: BMJ.2015.028205 Article Type: Research BMJ Journal: BMJ Date Submitted by the Author: 17-Jul-2015 Complete List of Authors: Welk, Blayne; Western University, McArthur, Eric; Institute for Clinical Evaluative Sciences,, Fraser, Lisa-Ann; Western University, Medicine Hayward, Jade; Institute for Clinical Evaluative Sciences,, Dixon, Stephanie; Institute for Clinical Evaluative Sciences,, Hwang, Joseph; Case Western Reserve University School of Medicine, Ordon, Michael; University of Toronto, Surgery (Urology) Keywords: BPH, Fall, Fracture, Alpha antgonist https://mc.manuscriptcentral.com/bmj Page 1 of 45 BMJ 1 2 The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist 3 4 1,2,3 2 4 2 5 Blayne Welk MD MSc , Eric McArthur MSc , Lisa-Ann Fraser MD MSc , Jade Hayward , 6 Stephanie Dixon MSc PhD 2,3 , Y. Joseph Hwang MSc 5, Michael Ordon MD MSc 6 7 8 1 DepartmentConfidential: of Surgery, Western University, For London Review, Ontario, Canada Only 9 2 Institute for Clinical Evaluative Sciences, London, Ontario, Canada 10 11 3 Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada 12 4 Department of Medicine, Western University, London, Ontario 13 5 MD Candidate, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA 14 6 Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada 15 16 17 Correspondence: 18 Blayne Welk, MD MSc 19 Assistant Professor, Division of Urology and Epidemiology and Biostatistics 20 Western University 21 Room B4-667 22 23 St Joseph's Health Care 24 268 Grosvenor Street London ON N6A 4V2 25 Telephone: 519 646-6367 | Fax: 519 646-6037 26 [email protected] 27 28 29 Addresses: 30 Mr McArthur: [email protected] 31 LHSC – Victoria Hospital 32 ELL-101, 800 Commissioners Rd.
    [Show full text]
  • Emcyt® Estramustine Phosphate Sodium Capsules DESCRIPTION
    Emcyt® estramustine phosphate sodium capsules DESCRIPTION Estramustine phosphate sodium, an antineoplastic agent, is an off-white powder readily soluble in water. EMCYT Capsules are white and opaque, each containing estramustine phosphate sodium as the disodium salt monohydrate equivalent to 140 mg estramustine phosphate, for oral administration. Each capsule also contains magnesium stearate, silicon dioxide, sodium lauryl sulfate, and talc. Gelatin capsule shells contain the following pigment: titanium dioxide. Chemically, estramustine phosphate sodium is estra-1,3,5(10)-triene-3,17-diol(17ß)-,3­ [bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate. It is also referred to as estradiol 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate. Estramustine phosphate sodium has an empiric formula of C23H30Cl2NNa2O6P•H2O, a calculated molecular weight of 582.4, and the following structural formula: CLINICAL PHARMACOLOGY Estramustine phosphate (Figure 1) is a molecule combining estradiol and nornitrogen mustard by a carbamate link. The molecule is phosphorylated to make it water soluble. 1 Estramustine phosphate taken orally is readily dephosphorylated during absorption, and the major metabolites in plasma are estramustine (Figure 2), the estrone analog (Figure 3), estradiol, and estrone. Prolonged treatment with estramustine phosphate produces elevated total plasma concentrations of estradiol that fall within ranges similar to the elevated estradiol levels found in prostatic cancer patients given conventional estradiol therapy. Estrogenic effects, as demonstrated by changes in circulating levels of steroids and pituitary hormones, are similar in patients treated with either estramustine phosphate or conventional estradiol. 2 The metabolic urinary patterns of the estradiol moiety of estramustine phosphate and estradiol itself are very similar, although the metabolites derived from estramustine phosphate are excreted at a slower rate.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Binding Characteristics of a Major Protein in Rat Ventral Prostate Cytosol That Interacts with Estramustine, a Nitrogen Mustard Derivative of 17ß-Estradiol
    [CANCER RESEARCH 39, 5155-5164, December 1979] 0008-5472/79/0039-OOOOS02.00 Binding Characteristics of a Major Protein in Rat Ventral Prostate Cytosol That Interacts with Estramustine, a Nitrogen Mustard Derivative of 17ß-Estradiol BjörnForsgren, Jan-Àke Gustafsson, Ake Pousette, and Bertil Hogberg AB Leo Research Laboratories. Pack. S-251 00 Helsingborg, Sweden [B.F.. B.H.], and Departments of Chemistry and Medical Nutrition. ¡J-ÄG.. A P.¡and Pharmacology [BH.], Karolinska Institute!. S-104 01 Stockholm 60. Sweden ABSTRACT causes atrophy of the testes and accessory sex organs; re duces the uptake of zinc by the prostate; depresses the 5a- The tissue distribution of [3H]estramustine, the dephospho- reductase, arginase, and acid phosphatase activities in the rylated metabolite of estramustine phosphate (Estracyt), in the male rat was compared to that of [3H]estradiol 30 min and 2 hr prostate; and affects lipid and carbohydrate metabolism (10, 11, 20, 29, 31 -33, 42). Although the observed effects in many following i.p. administration. In contrast to estradiol, estramus respects are similar to estrogenic effects, several experimental tine was found to be efficiently concentrated in the ventral and clinical results indicate that estramustine phosphate affects prostate gland by a soluble protein. The binding characteristics normal and neoplastic prostate tissue in a way that cannot be of this protein were studied in vitro using cytosol preparations attributed solely to its antigonadotropic or weak estrogenic of the gland. With a dextran-coated charcoal technique, the properties (15, 16, 30, 38). protein was found to bind estramustine with a broad pH opti Plym Forshell and Nilsson (35), using labeled compounds (1 mum between pH 7 and pH 8.5, with an apparent Kd of 10 to to 10 mg/kg body weight), found considerably higher levels of 30 nw, and with a binding capacity of about 5 nmol/mg cytosol radioactivity in the rat ventral prostate following i.v.
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Appendix C Medication Tables
    Appendix C Medication Tables Note: The medication tables are not meant to be inclusive lists of all available therapeutic agents. Approved medication tables will be updated regularly. Discrepancies must be reported. See Resource Section of this manual for additional contact information. Release Notes: Aspirin Table Version 1.0 Table 1.1 Aspirin and Aspirin-Containing Medications Acetylsalicylic Acid Acuprin 81 Alka-Seltzer Alka-Seltzer Morning Relief Anacin Arthritis Foundation Aspirin Arthritis Pain Ascriptin Arthritis Pain Formula ASA ASA Baby ASA Baby Chewable ASA Baby Coated ASA Bayer ASA Bayer Children's ASA Buffered ASA Children's ASA EC ASA Enteric Coated ASA/Maalox Ascriptin Aspergum Aspir-10 Aspir-Low Aspir-Lox Aspir-Mox Aspir-Trin Aspirbuf Aspircaf Aspirin Aspirin Baby Aspirin Bayer Aspirin Bayer Children's Aspirin Buffered Aspirin Child Aspirin Child Chewable Aspirin Children's Aspirin EC Aspirin Enteric Coated Specifications Manual for National Appendix C-1 Hospital Quality Measures Table 1.1 Aspirin and Aspirin-Containing Medications (continued) Aspirin Litecoat Aspirin Lo-Dose Aspirin Low Strength Aspirin Tri-Buffered Aspirin, Extended Release Aspirin/butalbital/caffeine Aspirin/caffeine Aspirin/pravachol Aspirin/pravastatin Aspirtab Bayer Aspirin Bayer Aspirin PM Extra Strength Bayer Children’s Bayer EC Bayer Enteric Coated Bayer Low Strength Bayer Plus Buffered ASA Buffered Aspirin Buffered Baby ASA Bufferin Bufferin Arthritis Strength Bufferin Extra Strength Buffex Cama Arthritis Reliever Child’s Aspirin Coated Aspirin
    [Show full text]
  • Estramustine Sodium Phosphate Capsules BP
    PRODUCT MONOGRAPH PrEMCYT* (estramustine sodium phosphate capsules B.P.) 140 mg/capsule Antineoplastic Pfizer Canada Inc Date of Revision: 17,300 Trans-Canada Highway 10 December 2015 Kirkland, Quebec H9J 2M5 Control No. 186447 * TM Pharmacia AB Pfizer Canada Inc, Licensee Pfizer Canada Inc 2015 1 PRODUCT MONOGRAPH NAME OF DRUG PrEMCYT Estramustine sodium phosphate capsules B.P. THERAPEUTIC CLASSIFICATION Antineoplastic CAUTION: EMCYT (ESTRAMUSTINE SODIUM PHOSPHATE) IS A POTENT DRUG AND SHOULD BE PRESCRIBED ONLY BY PHYSICIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC DRUGS (SEE WARNINGS & PRECAUTIONS). BLOOD COUNTS, AS WELL AS RENAL AND HEPATIC FUNCTION TESTS, SHOULD BE PERFORMED REGULARLY. DISCONTINUE THE DRUG IF ABNORMAL RENAL OR HEPATIC FUNCTION IS SEEN. CAPSULES SHOULD NOT BE OPENED. ACTION Emcyt (estramustine sodium phosphate) has a dual mode of action. The intact molecule acts as an anti-mitotic agent and after hydrolysis of the carbamate ester bridge the released estrogens exert an anti-gonadotrophic effect. The low level of clinically manifested side effects may be due to the fact that estramustine binds to a protein present in the tumor tissue, which results in an accumulation of the drug at the target site. 2 INDICATIONS The treatment of metastatic prostatic carcinoma (stage D) in patients whose disease is refractory to hormonal therapy. Emcyt (estramustine sodium phosphate) may produce either a stabilization or regression of the disease process and improvement in ability to function. CONTRAINDICATIONS Emcyt should not be used in patients with any of the following conditions: * known hypersensitivity to either estradiol or to nitrogen mustard * severe hepatic or cardiac disease * active thrombophlebitis or thromboembolic disorders WARNINGS Emcyt (estramustine sodium phosphate) should be used with caution in patients with a history of thrombophlebitis, thrombosis or thromboembolic disorders, especially if associated with estrogen therapy.
    [Show full text]
  • Controversies in the Management of Advanced Prostate Cancer
    British Journal of Cancer (1999) 79(1), 146–155 © 1999 Cancer Research Campaign Controversies in the management of advanced prostate cancer CJ Tyrrell Oncology Research Unit, Derriford Hospital, Plymouth, UK Summary For advanced prostate cancer, the main hormone treatment against which other treatments are assessed is surgical castration. It is simple, safe and effective, however it is not acceptable to all patients. Medical castration by means of luteinizing hormone-releasing hormone (LH-RH) analogues such as goserelin acetate provides an alternative to surgical castration. Diethylstilboestrol, previously the only non-surgical alternative to orchidectomy, is no longer routinely used. Castration reduces serum testosterone by around 90%, but does not affect androgen biosynthesis in the adrenal glands. Addition of an anti-androgen to medical or surgical castration blocks the effect of remaining testosterone on prostate cells and is termed combined androgen blockade (CAB). CAB has now been compared with castration alone (medical and surgical) in numerous clinical trials. Some trials show advantage of CAB over castration, whereas others report no significant difference. The author favours the view that CAB has an advantage over castration. No study has reported that CAB is less effective than castration. Of the anti-androgens which are available for use in CAB, bicalutamide may be associated with a lower incidence of side-effects compared with the other non-steroidal anti-androgens and, in common with nilutamide, has the advantage of once-daily dosing. Only one study has compared anti-androgens within CAB: bicalutamide plus LH-RH analogue and flutamide plus LH-RH analogue. At 160- week follow-up, the groups were equivalent in terms of survival and time to progression.
    [Show full text]
  • NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010
    NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document is in the public domain and may be freely copied or reprinted. DISCLAIMER Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to Web sites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these Web sites. ORDERING INFORMATION To receive documents or other information about occupational safety and health topics, contact NIOSH at Telephone: 1–800–CDC–INFO (1–800–232–4636) TTY:1–888–232–6348 E-mail: [email protected] or visit the NIOSH Web site at www.cdc.gov/niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews. DHHS (NIOSH) Publication Number 2010−167 September 2010 Preamble: The National Institute for Occupational Safety and Health (NIOSH) Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings was published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/). In Appendix A of the Alert, NIOSH identified a sample list of major hazardous drugs. The list was compiled from infor- mation provided by four institutions that have generated lists of hazardous drugs for their respec- tive facilities and by the Pharmaceutical Research and Manufacturers of America (PhRMA) from the American Hospital Formulary Service Drug Information (AHFS DI) monographs [ASHP/ AHFS DI 2003].
    [Show full text]
  • 2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
    NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document is in the public domain and may be freely copied or reprinted. Disclaimer Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to Web sites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these Web sites. Ordering Information To receive documents or other information about occupational safety and health topics, contact NIOSH at Telephone: 1–800–CDC–INFO (1–800–232–4636) TTY:1–888–232–6348 E-mail: [email protected] or visit the NIOSH Web site at www.cdc.gov/niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews. DHHS (NIOSH) Publication Number 2012−150 (Supersedes 2010–167) June 2012 Preamble: The National Institute for Occupational Safety and Health (NIOSH) Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings was published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/). In Appendix A of the Alert, NIOSH identified a sample list of major hazardous drugs.
    [Show full text]
  • BCBSNM/HMONM Therapeutic Class Drug List (Formulary) 2004
    BCBSNM/HMONM Therapeutic Class Drug List (Formulary) 2004 I. Antineoplastics and Immunosuppressants A. Antineoplastics B. Immunosuppressants II. Blood Modifiers A. Anticoagulants B. Platelet Aggregation Inhibitors C. Miscellaneous III. Cardiovascular Agents A. ACE Inhibitors B. Alpha Blockers C. Angiotensin II Receptor Blockers D. Antiarrhythmics and Cardiac Glycosides E. Beta Blockers F. Calcium Channel Blockers G. Diuretics H. Lipid Lowering Agents I. Nitrates J. Miscellaneous IV. Central Nervous System A. Alzheimer’s Disease B. Analgesics C. Migraine D. Parkinson’s Disease E. Seizures V. Dermatology A. Acne B. Bacterial Infections C. Corticosteroids D. Fungal Infections E. Psoriasis F. Scabies and Pediculosis G. Viral Infections H. Miscellaneous VI. Ear, Nose, and Throat A. Ear B. Nose C. Throat and Mouth Page 1 of 35 web\web documents\drug formularies\print formulary\print_tc_formulary_2004.doc BCBSNM / HMONM Therapeutic Class Drug List 2004 VII. Endocrinology A. Adrenal Corticosteroids B. Diabetes Mellitus C. Osteoporosis D. Paget's Disease E. Thyroid Modifiers F. Miscellaneous VIII. Gastrointestinal A. Diarrhea B. Emesis C. Inflammatory Bowel Disease D. Pancreatic Enzymes E. Reflux (GERD) F. Spasm G. Ulcers H. Miscellaneous IX. Infectious Diseases A. Antimicrobials B. Antifungals C. Antivirals D. Miscellaneous E. Web site reference X. Musculoskeletal A. Gout B. Rheumatoid and Osteoarthritis C. Skeletal Muscle Relaxants XI. OB-GYN A. Contraceptives B. Endometriosis C. Menopausal/Postmenopausal Symptoms D. Vaginal Infections E. Miscellaneous Page 2 of 35 web\web documents\drug formularies\print formulary\print_tc_formulary_2004.doc BCBSNM / HMONM Therapeutic Class Drug List 2004 XII. Ophthalmic A. Allergy B. Anti-inflammatories C. Infections D. Glaucoma E. Miscellaneous XIII. Psychiatric A. Alcohol Deterrents B.
    [Show full text]
  • Appendix B - Product Name Sorted by Applicant
    JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
    [Show full text]